JP2012247438A5 - - Google Patents

Download PDF

Info

Publication number
JP2012247438A5
JP2012247438A5 JP2012198693A JP2012198693A JP2012247438A5 JP 2012247438 A5 JP2012247438 A5 JP 2012247438A5 JP 2012198693 A JP2012198693 A JP 2012198693A JP 2012198693 A JP2012198693 A JP 2012198693A JP 2012247438 A5 JP2012247438 A5 JP 2012247438A5
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
leukemia
igfbp2
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012198693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012247438A (ja
JP5816147B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012247438A publication Critical patent/JP2012247438A/ja
Publication of JP2012247438A5 publication Critical patent/JP2012247438A5/ja
Application granted granted Critical
Publication of JP5816147B2 publication Critical patent/JP5816147B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012198693A 2006-06-30 2012-09-10 Igfbp2インヒビター Active JP5816147B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81800406P 2006-06-30 2006-06-30
US60/818,004 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009518353A Division JP5399900B2 (ja) 2006-06-30 2007-06-29 Igfbp2インヒビター

Publications (3)

Publication Number Publication Date
JP2012247438A JP2012247438A (ja) 2012-12-13
JP2012247438A5 true JP2012247438A5 (cg-RX-API-DMAC7.html) 2013-03-28
JP5816147B2 JP5816147B2 (ja) 2015-11-18

Family

ID=38783580

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009518353A Active JP5399900B2 (ja) 2006-06-30 2007-06-29 Igfbp2インヒビター
JP2012198693A Active JP5816147B2 (ja) 2006-06-30 2012-09-10 Igfbp2インヒビター
JP2013024276A Pending JP2013127473A (ja) 2006-06-30 2013-02-12 Igfbp2インヒビター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009518353A Active JP5399900B2 (ja) 2006-06-30 2007-06-29 Igfbp2インヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013024276A Pending JP2013127473A (ja) 2006-06-30 2013-02-12 Igfbp2インヒビター

Country Status (7)

Country Link
US (2) US20080112888A1 (cg-RX-API-DMAC7.html)
EP (2) EP2405270B1 (cg-RX-API-DMAC7.html)
JP (3) JP5399900B2 (cg-RX-API-DMAC7.html)
AT (1) ATE537450T1 (cg-RX-API-DMAC7.html)
CA (1) CA2655997A1 (cg-RX-API-DMAC7.html)
ES (1) ES2427924T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008005469A2 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
CA2589885A1 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
EP2405270B1 (en) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
US8834873B2 (en) * 2006-11-01 2014-09-16 George Mason Research Foundation, Inc. Method for detecting and controlling cancer
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009079587A2 (en) * 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
EP2259797A2 (en) * 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
AU2009256246B2 (en) * 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
WO2009154645A1 (en) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Methods for the treatment of central nervous system tumors
BRPI0915448A2 (pt) * 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
ME02377B (me) 2008-12-12 2016-06-20 Boehringer Ingelheim Int Anti-igf antitijela
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8906374B2 (en) 2010-04-20 2014-12-09 Cedars-Sinai Medical Center Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
US8741288B2 (en) * 2010-07-07 2014-06-03 Chang Gung Medical Foundation, Linkou Branch Protein markers for detecting liver cancer and method for identifying the markers thereof
WO2012006681A1 (en) 2010-07-14 2012-01-19 Commonwealth Scientific And Industrial Research Organisation Diagnostic for colorectal cancer
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012019031A2 (en) * 2010-08-04 2012-02-09 Ohio University Biomarkers for growth hormone disorders
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
EP2668508A2 (en) * 2011-01-27 2013-12-04 Virginia Commonwealth University Diagnostic and prognostic markers for metastasis
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
CN102703502A (zh) * 2012-02-27 2012-10-03 同昕生物技术(北京)有限公司 Rta蛋白的制备方法及其在鼻咽癌检测试剂中的应用
CN114966050A (zh) * 2012-03-18 2022-08-30 镜株式会社 疾病样品分析装置、分析系统及分析方法
RS58553B1 (sr) * 2012-08-09 2019-05-31 Inst Nat Sante Rech Med Dijagnostika zatajenja srca
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
MX2015005160A (es) 2012-11-02 2015-07-17 Repros Therapeutics Inc Trans-clomifeno para uso en terapia de cancer.
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
HUE043373T2 (hu) 2013-06-06 2019-08-28 Inst Nat Sante Rech Med Szívelégtelenség utáni rehospitalizáció biomarkere
EP3102233B1 (en) 2014-02-05 2025-12-17 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
US20230084477A1 (en) 2021-08-10 2023-03-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025054482A1 (en) * 2023-09-06 2025-03-13 Viridian Therapeutics, Inc. Pharmaceutical compositions of anti-igf-1r antibodies

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5656655A (en) 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
PL204437B1 (pl) 1999-05-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
EP1191941A4 (en) * 1999-06-21 2006-12-13 Murdoch Childrens Res Inst METHOD OF PROPHYLAXIS AND / OR TREATMENT OF CLINICAL DISORDERS
GEP20053530B (en) 1999-10-19 2005-05-25 Merck & Co Inc Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
WO2002006484A1 (en) * 2000-07-19 2002-01-24 Takara Bio Inc. Method of detecting cancer
WO2002032861A2 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
GEP20084484B (en) 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
IL157705A0 (en) * 2001-03-14 2004-03-28 Genentech Inc Igf antagonist peptides
AU2003216748B2 (en) 2002-01-18 2009-07-16 Pierre Fabre Medicament Novel anti-IGF-IR antibodies and uses thereof
FR2834990A1 (fr) 2002-01-18 2003-07-25 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2834900B1 (fr) 2002-01-18 2005-07-01 Pf Medicament Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
FR2834991B1 (fr) 2002-01-18 2004-12-31 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
CA2480325A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1543009A4 (en) 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazine KINASE INHIBITORS
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2514231A1 (en) 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ.ホフマン−ラ ロシュ アーゲー インスリン様成長因子i受容体に対する抗体及びその使用
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2004111603A2 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
CA2589885A1 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
EP2405270B1 (en) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
US8492328B2 (en) * 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Similar Documents

Publication Publication Date Title
JP2012247438A5 (cg-RX-API-DMAC7.html)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
JP2011519868A5 (cg-RX-API-DMAC7.html)
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2011515478A5 (cg-RX-API-DMAC7.html)
JP2019503674A5 (cg-RX-API-DMAC7.html)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
JP5816147B2 (ja) Igfbp2インヒビター
JP2016519091A5 (cg-RX-API-DMAC7.html)
MX2010012064A (es) Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
JP2017538673A5 (cg-RX-API-DMAC7.html)
RU2017145267A (ru) Модуляторы протеолиза на основе имидов и связанные с ними способы применения
CA2718918A1 (en) Methods for treating or preventing colorectal cancer
JP2013078341A (ja) 抗igf1r療法に対する感受性のバイオマーカー
JP2014516964A5 (cg-RX-API-DMAC7.html)
CA2834566A1 (en) Therapeutic anti-igf1r combinations
US10512651B2 (en) Inhibition of MK2 in the treatment of cancer
JPWO2021055705A5 (cg-RX-API-DMAC7.html)
US20160184356A1 (en) Arsenic-based treatment of cancers and inflammatory disorders
US20240122906A1 (en) Methods of treating melanoma with ripretinib
US20240209454A1 (en) Use of mutational signatures for multiple cancer types
US8470297B1 (en) FDG-pet evaluation of Ewing's sarcoma sensitivity
CN117693341A (zh) 用于治疗黑素瘤的瑞普替尼
EP4626422A2 (en) Morphic forms of a mutant braf degrader and methods of manufacture thereof